181 related articles for article (PubMed ID: 23835252)
1. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
4. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
Malempati S; Weigel B; Ingle AM; Ahern CH; Carroll JM; Roberts CT; Reid JM; Schmechel S; Voss SD; Cho SY; Chen HX; Krailo MD; Adamson PC; Blaney SM
J Clin Oncol; 2012 Jan; 30(3):256-62. PubMed ID: 22184397
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.
Wagner LM; Fouladi M; Ahmed A; Krailo MD; Weigel B; DuBois SG; Doyle LA; Chen H; Blaney SM
Pediatr Blood Cancer; 2015 Mar; 62(3):440-4. PubMed ID: 25446280
[TBL] [Abstract][Full Text] [Related]
9. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Rajan A; Carter CA; Berman A; Cao L; Kelly RJ; Thomas A; Khozin S; Chavez AL; Bergagnini I; Scepura B; Szabo E; Lee MJ; Trepel JB; Browne SK; Rosen LB; Yu Y; Steinberg SM; Chen HX; Riely GJ; Giaccone G
Lancet Oncol; 2014 Feb; 15(2):191-200. PubMed ID: 24439931
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
[TBL] [Abstract][Full Text] [Related]
11. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
Weigel B; Malempati S; Reid JM; Voss SD; Cho SY; Chen HX; Krailo M; Villaluna D; Adamson PC; Blaney SM
Pediatr Blood Cancer; 2014 Mar; 61(3):452-6. PubMed ID: 23956055
[TBL] [Abstract][Full Text] [Related]
14. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
Higano CS; Berlin J; Gordon M; LoRusso P; Tang S; Dontabhaktuni A; Schwartz JD; Cosaert J; Mehnert JM
Invest New Drugs; 2015 Apr; 33(2):450-62. PubMed ID: 25749986
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
17. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
18. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Olmos D; Postel-Vinay S; Molife LR; Okuno SH; Schuetze SM; Paccagnella ML; Batzel GN; Yin D; Pritchard-Jones K; Judson I; Worden FP; Gualberto A; Scurr M; de Bono JS; Haluska P
Lancet Oncol; 2010 Feb; 11(2):129-35. PubMed ID: 20036194
[TBL] [Abstract][Full Text] [Related]
20. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
